Lamivudine/Raltegravir Potassium

拉米夫定/拉替拉韦钾

Report date: 2022/12/07 18:11:09

Base Information

Drug NameLamivudine/Raltegravir Potassium
Drug Alias Name拉替拉韦钾/拉米夫定Lamivudine and raltegravirLamivudine and Raltegravir PotassiumLamivudine - raltegraviraltegravir potassium and lamivudine +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHIV integrase inhibitorsReverse transcriptase inhibitors
TargetsHIV integraseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/02/06
Country/TerritoryUnited StatesEU
CombinationsYes LamivudineRaltegravir Potassium
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck & Co IncMerck Sharp & Dohme Ltd
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeJ05AR16
Related LinksWikipediaKEGG